Iatrogenic Cushing's Syndrome due to Coadministration of Ritonavir and Inhaled Budesonide in an Asthmatic Human Immunodeficiency Virus Infected Patient
- 26 July 2010
- journal article
- case report
- Published by Informa UK Limited in Journal of Asthma
- Vol. 47 (7), 830-831
- https://doi.org/10.3109/02770903.2010.485666
Abstract
Iatrogenic Cushing's syndrome (CS) is caused by exposure to glucocorticoids and may be promoted by interaction with additional drugs. It is well known in asthmatic human immunodeficiency virus (HIV)-infected patients treated with inhaled fluticasone with ritonavir-containing antiretroviral regimen (cART). The authors present an asthmatic HIV-infected Ethiopian woman, treated with fluticasone/salmeterol, commencing cART with tenofovir, emtricitabine, and lopinavir/ritonavir. During 7 months she gained 9 kg and hyperpigmentation, mild edema, marked abdominal striae, and increase in blood pressure were noted. Plasma am and urine free cortisol levels confirmed CS diagnosis and fluticasone was discontinued. Complete resolution of CS occurred within 2 months. However, frequent asthma symptoms required resumption of inhaled corticosteroid (ICS) treatment, and budesonide/formeterol was prescribed. Soon reemergence of symptomatic CS was noted. Ritonavir dose was halved, but CS symptoms continued to develop. Budesonide was stopped and montelukast initiated. Resolution of cushingoid symptoms was observed within weeks. Corticosteroids are metabolized by cytochrome P450 3A4 (CYP3A4). Fluticasone has the longest glucocorticoid receptor-binding half-life and is 300 times more lipophilic than budesonide. Inhaled fluticasone possesses a high suppression rate of hypothalamic-pituitary-adrenal axis. Ritonavir, a potent CYP3A4 inhibitor, may inhibit corticosteroid degradation and increase its accumulation. Inhaled budesonide is less likely to cause adrenal suppression. Diagnosing Cushing's syndrome presents a clinical challenge due to similarities with clinical manifestations and side effects related to cART. In patients treated with inhaled or intranasal corticosteroids together with cART there may be a higher incidence of iatrogenic CS. CS should be looked for, and management considered carefully.Keywords
This publication has 12 references indexed in Scilit:
- Drug interactions between inhaled corticosteroids and enzymatic inhibitorsEuropean Journal of Clinical Pharmacology, 2009
- Iatrogenic Cushing's Syndrome in HIV-Infected Patients Receiving Ritonavir and Inhaled Fluticasone: Description of 4 New Cases and Review of the LiteratureJournal of the International Association of Physicians in AIDS Care, 2009
- Iatrogenic Cushing Syndrome after Epidural Triamcinolone Injections in an HIV Type 1–Infected Patient Receiving Therapy with Ritonavir‐LopinavirClinical Infectious Diseases, 2008
- Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literatureHIV Medicine, 2008
- Ritonavir and fluticasone: Beware of this potentially fatal combinationThe Journal of Pediatrics, 2006
- Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasoneThe Journal of Pediatrics, 2006
- Prednisolone Pharmacokinetics in the Presence and Absence of Ritonavir After Oral Prednisone Administration to Healthy VolunteersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Iatrogenic Cushing’s Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibitors: Six CasesJournal of Clinical Endocrinology & Metabolism, 2005
- Comparison of Inhaled CorticosteroidsAnnals of Pharmacotherapy, 1998
- Pharmacodynamics and pharmacokinetics of inhaled glucocorticoidsJournal of Allergy and Clinical Immunology, 1996